Edwards Lifesciences Corp (NYSE:EW) shares traded 1.76% higher at $94.68 on Wall Street last session.
EW stock price is now 13.05% away from the 50-day moving average and 20.65% away from the 200-day moving average. The market capitalization of the company currently stands at $56.93B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On February 02, 2024, Wells Fargo Upgraded its previous ‘Equal Weight’ rating to ‘Overweight’ on the stock keeping its target price maintained at $94, while ‘Evercore ISI’ rates the stock as ‘In-line’
In other news, BOBO DONALD E JR, CVP,Strategy/Corp Development sold 14,500 shares of the company’s stock on Mar 13 ’24. The stock was sold for $1,319,696 at an average price of $91.01. Upon completion of the transaction, the CVP,Strategy/Corp Development now directly owns 39,503 shares in the company, valued at $3.74 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 11 ’24, CVP, EMEACLA and JAPAC Lemercier Jean-Luc M sold 14,400 shares of the business’s stock. A total of $1,320,149 was realized by selling the stock at an average price of $91.68. This leaves the insider owning 173,584 shares of the company worth $16.43 million. A total of 1.58% of the company’s stock is owned by insiders.
During the past 12 months, Edwards Lifesciences Corp has had a low of $60.57 and a high of $95.27. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.38, and a quick ratio of 2.40. According to the stock market information, the enterprise value for the company is $55.98B, which is based on a 41.14 price-to-earnings ratio, a 4.41 price-to-earnings-growth ratio, and a beta of 1.05. The fifty day moving average price for EW is $84.13 and a two-hundred day moving average price translates $78.52 for the stock.
The latest earnings results from Edwards Lifesciences Corp (NYSE: EW) was released for Dec, 2023. According to the Medical Devices Company, earnings per share came in at $0.64, inline with analysts’ expectations of $0.64. This compares to $0.65 EPS in the same period last year. The net profit margin was 23.35% and return on equity was 22.52% for EW. The company reported revenue of $1.53 billion for the quarter, compared to $1.35 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.78 percent. For the current quarter, analysts expect EW to generate $1.57B in revenue.
